Keros Therapeutics (KROS) had its price target lowered by Wells Fargo & Company from $23.00 to $20.00. They now have an "overweight" rating on the stock.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Keros Therapeutics Appoints Charles Newton to its Board of Directors
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.